Hungarian company Egis Pharmaceuticals has acquired the Russian skin care and womenʼs healthcare product portfolio of its Croatian peer, Jadran-Galenski Laboratorij. The cost of the transaction was not disclosed. The investment is in line with Egis’ commitment to expand its activity on strategic markets and enter new segments and therapeutic areas. D-Panthenol, the skin repair and wound-healing product acquired under the deal, is the second largest brand on Russia’s dexpanthenol market and becomes Egis’ fourth largest product family and the second largest in its OTC segment based on turnover.
